Table 4.
Adverse events associated with apatinib in patients with sorafenib-resistant advanced HCC.
| Adverse event | All grades. n (%) | Grade 1–2. n (%) | Grade 3–4. n (%) |
|---|---|---|---|
| Weight loss | 45 (77.6) | 45 (77.6) | 0 |
| HFSR | 42 (72.4) | 39 (67.2) | 3 (5.2) |
| Hypertension | 35 (60.3) | 33 (56.9) | 3 (5.2) |
| Fatigue | 31 (53.4) | 31 (53.4) | 0 |
| Alopecia | 30 (51.7) | 30 (51.7) | 0 |
| Diarrhea | 27 (46.6) | 25 (43.1) | 2 (3.4) |
| Anorexia | 21 (36.2) | 19 (32.8) | 2 (3.4) |
| Proteinuria | 16 (27.6) | 15 (25.9) | 2 (3.4) |
| Pharyngolaryngeal pain | 6 (10.3) | 5 (8.6) | 1 (1.7) |
| Hoarseness | 7 (12.1) | 7 (12.1) | 0 |
| Oral mucositis | 4 (9.3) | 3 (5.1) | 1 (1.7) |
| Headache/dizziness | 5 (8.5) | 3 (5.1) | 2 (3.4) |
| Stomach ache | 5 (8.5) | 4 (6.8) | 1 (1.7) |
| Vomiting | 4 (6.8) | 4 (6.8) | 0 |
| Dysphagia | 3 (5.1) | 2 (3.4) | 1 (1.7) |
HCC, hepatocellular carcinoma; HFSR, hand-foot skin reaction.